Kooperativer Bibliotheksverbund

UID:

Format: 1 Online-Ressource , Illustrationen

Edition: 7th edition

ISBN: 9783030022785

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-3-030-02277-8

Language: English

Keywords: Periphere Stammzellentransplantation ; Zelltransplantation ; Bluttransfusion

URL: Volltext  (kostenfrei)

UID:

Format: 1 Online-Ressource (XL, 702 p. 56 illus., 38 illus. in color)

Edition: Seventh Edition

ISBN: 9783030022785

Note: Erscheint als Open Access bei Springer

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-3-030-02277-8

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-3-030-02279-2

Language: English

Keywords: Periphere Stammzellentransplantation ; Zelltransplantation ; Bluttransfusion

DOI: 10.1007/978-3-030-02278-5

URL: Volltext  (kostenfrei)

URL: Volltext  (kostenfrei)

Author information: Kröger, Nicolaus 1959-

Author information: Dufour, Carlo

UID:

Format: 1 online resource (689 pages)

Edition: 7th ed.

ISBN: 9783030022785

Content: Intro -- Preface -- Acknowledgment -- Contents -- Contributors -- About the Editors -- Abbreviations -- Part I: Introduction Topic leaders: Mohamad Mohty and Jane Apperley -- 1: HSCT: Historical Perspective -- 1.1 Introduction -- 1.2 Early Enthusiasm and Disappointment -- 1.3 Back to the Laboratory: Focus on Animal Studies -- 1.4 Resuming Clinical Transplantation: 1968-1980s -- 1.5 Moving Ahead: The 1990s and Beyond -- References -- 2: The EBMT: History, Present, and Future -- 2.1 Introduction -- 2.2 The Past: Development of HSCT and EBMT -- 2.3 The Present -- 2.4 The Future -- References -- 3: The Role of Unrelated Donor Registries in HSCT -- 3.1 Introduction -- 3.1.1 From Anthony Nolan to 32 Million Volunteer Donors Worldwide -- 3.1.2 Registry: Structure and Duties -- 3.2 Current Landscape -- 3.2.1 Ethnic Diversity and Chance to Find a Donor -- 3.2.2 Donor Profile -- 3.2.3 Recruitment, Retention and Data Confidentiality -- 3.3 Connections and Worldwide Collaboration -- 3.3.1 WMDA -- 3.3.2 Quality and Accreditation -- 3.3.3 Network Formalities -- 3.4 Challenges and Opportunities -- 3.4.1 Donor Attrition -- 3.4.2 Ethical Challenges -- 3.4.3 Donor Pool HLA Diversity -- 3.5 Future Developments -- 3.5.1 New Level of HLA Matching -- 3.5.2 Related Donors Provision and Follow-Up -- 3.5.3 Advisory Services Provided by Registries -- References -- 4: The HSCT Unit -- 4.1 Introduction -- 4.2 Inpatient Unit -- 4.3 Ancillary Medical Services -- 4.4 Outpatient Unit -- 4.5 Blood Bank -- 4.6 Laboratory -- 4.7 HLA Typing Lab -- 4.8 Stem Cell Collection -- 4.9 Stem Cell Processing Facility -- 4.10 Radiology -- 4.11 Pharmacy -- 4.12 Staffing and Human Resources -- 4.13 Institutional Database and Data Manager -- 4.14 Quality Control -- 4.15 Transplant Coordinator -- Recommended References.

Note: Description based on publisher supplied metadata and other sources

Additional Edition: ISBN 9783030022778

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 9783030022778

Language: English

Keywords: Handbooks and manuals

URL: lizenzpflichtig

URL: R2 Digital Library

URL: ProQuest Ebook Central

URL: SpringerLink

UID:

Format: XL, 702 p. 56 illus., 38 illus. in color. , online resource.

Edition: 7th ed. 2019.

ISBN: 9783030022785

Content: This Open Access 7th edition of the European Society for Blood and Marrow Transplantation (EBMT) handbook addresses the latest developments and innovations in hematopoietic stem cell transplantation and cellular therapy. Consisting of 93 chapters, it has been written by 175 leading experts in the field. Discussing all types of stem cell and bone marrow transplantation, including haplo-identical stem cell and cord blood transplantation, it also covers the indications for transplantation, the management of early and late complications as well as the new and rapidly evolving field of cellular therapies. This book provides an unparalleled description of current practices to enhance readers’ knowledge and practice skills.

Note: Part 1. Introduction -- 1. HSCT: Historical perspective -- 2. The EBMT: History, present and future -- 3. The role of unrelated donor registries in HSCT -- 4. The HSCT Unit -- 5. JACIE accreditation of HSCT programs -- 6. Statistical methods in HSCT and Cellular Therapies -- Part 2. Biological aspects -- 7. Biological properties of HSC: scientific basis for HSCT -- 8. Biological properties of cells other than HSC -- 9. Histocompatibility -- 10. Clinical & biological concepts for mastering Immune reconstitution after HSCT: towards practical guidelines and greater harmonization -- Part 3. Methodology and clinical aspects -- 11. Evaluation and counselling of candidates -- 12. Donor selection for adults and pediatrics -- 13. Conditioning -- 14. Bone marrow harvesting for HSCT -- 15. Mobilization and collection of HSC -- 16. Collection of HSC in children -- 17. Processing, cryopreserving, and controlling the quality of HSCs -- 18. Procurement and management of cord blood -- 19. Graft manipulation -- 20. Documentation of engraftment and chimerism after HSCT -- 21. Short and long-term controls after HSCT -- Part 4. General management of the patient -- 22. Vascular access -- 23. Transfusion support -- 24. Nutritional support -- 25. GVHD prophylaxis (immunosuppression) -- 26. Management ATG (SIRS) -- 27. Infections control and isolation procedures -- 28. General management of the patient; Specific aspects of children -- 29. Vaccinations -- 30. Psychological morbidity and support -- 31. Clinical relevant drug interactions in HSCT -- 32. Role of nursing in HSCT -- 33. Ethical issues in HSCT -- 34. Quality of life assessment after HSCT for pediatric and adults -- Part 5. HSCT complications and management -- 35. Neutropenic fever -- 36. Bacterial infections -- 37. Invasive fungal infections -- 38. Viral infections -- 39. Other life-threatening infections -- 40. Bleeding and thrombotic complications -- 41. Graft failure -- 42. Early complications of endothelial origin -- 43. Acute Graft-versus-Host Disease -- 44. Chronic Graft-versus-Host Disease -- 45. Post-transplant lymphoproliferative syndromes -- 46. Iron overload -- 47. Secondary neoplasia (other than PTLPS) -- Part 6. Specific organ complications -- 48. Ocular and oral complications -- 49. Hepatic complications -- 50. Gastrointestinal complications -- 51. Hemorrhagic cystitis and renal dysfunction -- 52. Non-infectious pulmonary complications -- 53. Neurological complications -- 54. Skin, hair and musculoskeletal complications -- 55. Cardiovascular diseases and metabolic syndrome -- 56. Endocrine disorders, fertility and sexual health -- Part 7. Prevention and management of relapse -- 57. Monitoring MRD in ALL and AML -- 58. Preventing/treating relapse with drugs -- 59. Delayed transfer of immune cells, or the art of Donor Lymphocyte Infusion -- 60. Cellular therapy with engineered T cells, efficacy and side effects -- 61. Mechanisms of Immune resistance -- 62. Regulatory Aspects of ATMP versus minimally manipulated immune cells -- Part 8. Specific modalities of HSCT and management -- 63. At-home HSCT -- 64. Umbilical cord blood transplantation in children and adults -- 65. Haploidentical HSCT -- 66. Photopheresis in adults and pediatrics -- 67. Overweight and obese patients -- 68. HSCT in elderly patients -- Part 9. Indications and results -- 69. Acute Myeloid Leukemia in adults -- 70. Acute Myeloid Leukemia in children -- 71. Acute Lymphoblastic Leukemia in adults -- 72. Acute lymphoblastic leukemia in children and adolescents -- 73. Myelodysplastic syndromes -- 74. Pediatric MDS including Refractory Cytopenia and Juvenile Myelomonocytic Leukemia -- 75. Myelodysplastic/myeloproliferative neoplasms -- 76. Myeloproliferative neoplasms -- 77. Severe aplastic anemia and PNH -- 78. Fanconi anemia and other hereditary Bone Marrow Failure syndromes -- 79. Hemoglobinopathies (Sickle Cell Disease and Thalassemia) -- 80. Multiple myeloma -- 81. Systemic light chain amyloidosis -- 82. POEMS syndrome and disease produced by other monoclonal immunoglobulins -- 83. Follicular lymphoma -- 84. Chronic lymphocytic leukemia -- 85. Diffuse large B cell lymphoma -- 86. Mantle cell lymphoma -- 87. Other T- and B-aggressive lymphomas and lymphomas associated to HIV -- 88. Classical Hodgkin’s lymphoma -- 89. Primary immunodeficiencies -- 90. Inborn error of metabolism and osteopetrosis -- 91. Autoimmune disease -- 92. Solid tumors.

In: Springer eBooks

Additional Edition: Printed edition: ISBN 9783030022778

Additional Edition: Printed edition: ISBN 9783030022792

Language: English

DOI: 10.1007/978-3-030-02278-5

URL: https://doi.org/10.1007/978-3-030-02278-5

URL: https://doi.org/10.1007/978-3-030-02278-5

UID:

Format: 1 online resource (689 pages)

Edition: 7th ed.

ISBN: 9783030022785

Note: Intro -- Preface -- Acknowledgment -- Contents -- Contributors -- About the Editors -- Abbreviations -- Part I: Introduction Topic leaders: Mohamad Mohty and Jane Apperley -- 1: HSCT: Historical Perspective -- 1.1 Introduction -- 1.2 Early Enthusiasm and Disappointment -- 1.3 Back to the Laboratory: Focus on Animal Studies -- 1.4 Resuming Clinical Transplantation: 1968-1980s -- 1.5 Moving Ahead: The 1990s and Beyond -- References -- 2: The EBMT: History, Present, and Future -- 2.1 Introduction -- 2.2 The Past: Development of HSCT and EBMT -- 2.3 The Present -- 2.4 The Future -- References -- 3: The Role of Unrelated Donor Registries in HSCT -- 3.1 Introduction -- 3.1.1 From Anthony Nolan to 32 Million Volunteer Donors Worldwide -- 3.1.2 Registry: Structure and Duties -- 3.2 Current Landscape -- 3.2.1 Ethnic Diversity and Chance to Find a Donor -- 3.2.2 Donor Profile -- 3.2.3 Recruitment, Retention and Data Confidentiality -- 3.3 Connections and Worldwide Collaboration -- 3.3.1 WMDA -- 3.3.2 Quality and Accreditation -- 3.3.3 Network Formalities -- 3.4 Challenges and Opportunities -- 3.4.1 Donor Attrition -- 3.4.2 Ethical Challenges -- 3.4.3 Donor Pool HLA Diversity -- 3.5 Future Developments -- 3.5.1 New Level of HLA Matching -- 3.5.2 Related Donors Provision and Follow-Up -- 3.5.3 Advisory Services Provided by Registries -- References -- 4: The HSCT Unit -- 4.1 Introduction -- 4.2 Inpatient Unit -- 4.3 Ancillary Medical Services -- 4.4 Outpatient Unit -- 4.5 Blood Bank -- 4.6 Laboratory -- 4.7 HLA Typing Lab -- 4.8 Stem Cell Collection -- 4.9 Stem Cell Processing Facility -- 4.10 Radiology -- 4.11 Pharmacy -- 4.12 Staffing and Human Resources -- 4.13 Institutional Database and Data Manager -- 4.14 Quality Control -- 4.15 Transplant Coordinator -- Recommended References. , 5: JACIE Accreditation of HSCT Programs -- 5.1 Introduction -- 5.2 Background -- 5.3 Impact of Accreditation in Clinical Practice -- 5.4 JACIE-FACT Accreditation System -- References -- 6: Statistical Methods in HSCT and Cellular Therapies -- 6.1 Introduction -- 6.2 Endpoints -- 6.3 Analysis of Time-to-Event Outcomes -- 6.3.1 Kaplan-Meier Curves -- 6.3.2 Cumulative Incidence Curves -- 6.3.3 Comparison of Groups -- 6.3.4 Proportional Hazards Regression Analysis -- 6.4 Advanced Methods -- 6.4.1 Multistate Models -- 6.4.2 Random Effect Models -- 6.4.3 Long-Term Outcomes: Relative Survival/Cure Models -- 6.4.4 Propensity Scores -- 6.4.5 Methods for Missing Values -- References -- Part II: Biological Aspects Topic leaders: Chiara Bonini and Jürgen Kuball -- 7: Biological Properties of HSC: Scientific Basis for HSCT -- 7.1 Introduction -- 7.2 Self-Renewal -- 7.3 Commitment and Differentiation: New Data Challenge the Historical View of Hematopoietic Hierarchy -- 7.4 The Bone Marrow Niches and Maintenance of Stemness (Fig. 7.1) -- 7.5 Preclinical Models of HSCT -- 7.6 Gene Transfer/Gene Editing/Gene Therapy Targeting HSC (Fig. 7.2) -- 7.7 Studying Dynamics of Hematopoietic Reconstitution upon HSCT (Fig. 7.3) -- 7.8 From Experimental Hematology to Medical Practices and Hematopoietic Cellular Therapies -- References -- 8: Biological Properties of Cells Other Than HSCs -- 8.1 Introduction -- 8.2 Conventional or Alpha-Beta T Cells -- 8.3 Unconventional T Cells -- 8.4 NK Cells -- 8.5 Mesenchymal Stromal Cells -- References -- 9: Histocompatibility -- 9.1 Introduction -- 9.2 The Biology of Histocompatibility -- 9.2.1 Major Histocompatibility Antigens -- 9.2.2 HLA Class I and II Structure and Function -- 9.2.3 HLA Polymorphism and Tissue Typing -- 9.2.4 T Cell Alloreactivity -- 9.3 HLA Matching in Allogeneic HSCT. , 9.3.1 Donor Types -- 9.3.2 Clinical Impact of HLA Mismatches -- 9.3.3 Models of High-Risk/Nonpermissive HLA Mismatches -- 9.3.4 Guidelines for UD Selection by Histocompatibility -- 9.4 Non-HLA Immunogenetic Factors -- 9.4.1 Overview -- 9.4.2 Clinical Impact of Non-HLA Immunogenetic Factors -- References -- 10: Clinical and Biological Concepts for Mastering Immune Reconstitution After HSCT: Toward Practical Guidelines and Greater Harmonization -- 10.1 Introduction/Background -- 10.2 Impact of Conditioning Regimens on Immune Reconstitution and Outcomes: Pharmacokinetics-Pharmacodynamics (PK-PD), Individualized Dosing -- 10.3 Graft Composition as an Additional Predictor for Immune Reconstitution and Clinical Outcomes -- 10.4 Immune Monitoring -- 10.4.1 Immune Cell Phenotyping -- 10.4.2 Immune Monitoring: Secretome Analyses -- 10.5 Summary -- References -- Part III: Methodology and Clinical Aspects Topic leaders: Arnon Nagler and Nicolaus Kröger -- 11: Evaluation and Counseling of Candidates -- 11.1 Evaluation of Candidates and Risk Factors for HSCT -- 11.1.1 Introduction -- 11.1.2 Candidates' Evaluation Work Flow -- 11.1.2.1 First Visit -- 11.1.2.2 Visit Preharvesting (Auto-HSCT) -- 11.1.2.3 Last Visit Before Admission -- 11.1.2.4 Medical History -- 11.1.2.5 Information to Provide (See Detailed Information in Counseling Section) -- 11.1.3 Complementary Explorations -- 11.1.4 Risk Assessment -- 11.1.4.1 Individual Risk Factors -- 11.1.4.2 Predictive Models -- Disease Risk Index (DRI) (Armand et al. 2012, 2014) -- EBMT Risk Score (Gratwohl et al. 1998, 2009) -- HCT-Comorbidity Index (HCT-CI) (Sorror et al. 2005) -- Pretransplantation Assessment of Mortality (PAM) Score (Parimon et al. 2006 -- Au et al. 2015) -- EBMT Machine Learning Algorithm (Shouval et al. 2015) -- 11.1.4.3 Predictive Capacity of These Models. , 11.1.5 Practical Applications of Risk Assessment -- 11.2 Counseling of Candidates -- 11.2.1 Introduction -- 11.2.2 Understanding the Benefit and Risk of Allogeneic Transplant -- 11.2.3 Understanding the Transplant Procedure: The Donor, the Conditioning Regimen, and the Clinical Complications -- 11.2.4 Logistics -- References -- 12: Donor Selection for Adults and Pediatrics -- 12.1 Introduction -- 12.2 Donor HLA Compatibility (See Chap. 9) -- 12.3 Donor Selection for Adult Patients -- 12.3.1 Donor Type (Summarized in Fig. 12.1) -- 12.3.1.1 Matched Related Siblings and Unrelated Donors -- 12.3.1.2 Haploidentical Related Donors -- 12.3.2 Role of Non-HLA Donor Characteristics -- 12.3.3 Donor Choice According to Stem Cell Source -- 12.3.4 Anti-HLA Antibodies -- 12.4 Donor Selection for Pediatric Patients -- 12.4.1 Pediatric Recipient Size -- 12.4.2 Indications -- 12.4.3 Donor Type -- 12.4.4 Haploidentical Donors in Pediatrics -- 12.4.5 Stem Cell Source -- 12.4.6 Other Donor-Recipient-Related Factors -- References -- 13: Conditioning -- 13.1 Overview -- 13.2 Total Body Irradiation -- 13.3 Myeloablative Non-TBI-Containing Conditioning -- 13.4 Nonmyeloablative, Reduced Intensity and Reduced Toxicity Conditioning -- 13.5 Conditioning Regimens for Allo-HSCT from Alternative Donors: MMUD, CB, and Haploidentical -- 13.6 Preparative Conditioning for Autologous HSCT -- References -- 14: Bone Marrow Harvesting for HSCT -- 14.1 Introduction -- 14.2 Indications for Considering and Possibly Selecting BM as a Preferred Source of HSC -- 14.3 Mobilized or Primed Marrow -- 14.4 Technique of BM Collection and Impact of the Dose of Nucleated Cells Infused -- 14.5 Complications of Bone Marrow Collections -- 14.6 Bone Marrow Cryopreservation -- 14.7 Quality Control for BM Harvesting and Cryopreservation -- 14.8 Conclusions -- References. , 15: Mobilization and Collection of HSC -- 15.1 Introduction -- 15.2 Strategies of Mobilization -- 15.2.1 Mobilization Without Chemotherapy ("Steady State") -- 15.2.2 Mobilization with Chemotherapy -- 15.3 CD34+ Cell Count and Timing of Leukapheresis -- 15.4 Target HSC Collection Count -- 15.5 Leukapheresis -- 15.6 Poor Mobilizer -- 15.7 Future Directions -- References -- 16: Collection of HSC in Children -- 16.1 Introduction -- 16.2 Bone Marrow Harvest (See Chap. 14) -- 16.3 Peripheral Blood Stem Cell Harvest -- 16.4 Risk Analysis BM Versus PBMNC -- 16.5 Pediatrics as Allogeneic Donors -- References -- 17: Processing, Cryopreserving and Controlling the Quality of HSCs -- 17.1 Assessment of HSCs by Measuring CD34 and the Presence of Other Cell Subsets -- 17.2 HSCs Cryopreservation -- 17.3 HSCs Quality Assessment -- 17.4 Collection of Reference (Retention) Samples for Quality Control -- References -- 18: Procurement and Management of Cord Blood -- 18.1 Introduction -- 18.2 Collection -- 18.3 Processing and Banking -- 18.3.1 UCB Cell Processing -- 18.3.2 Testing and Quality Assessment -- 18.4 Selecting CBU for Transplantation -- References -- 19: Graft Manipulation -- 19.1 Introduction -- 19.2 Graft Manipulation -- 19.2.1 Physical Manipulations -- 19.2.1.1 Volume Reduction -- 19.2.1.2 Washing to Reduce Plasma Antibodies or Anticoagulants -- 19.2.1.3 Depletion of Erythrocytes -- 19.2.2 Immunomagnetic Procedures -- 19.2.2.1 CD34 Enrichment -- 19.2.2.2 CD133 Enrichment -- 19.2.2.3 T-Cell Depletion -- CD3 Depletion -- TcRαβ Depletion -- CD19 Depletion -- Stem Cell Boosts -- 19.2.3 DLI and T Cells -- 19.2.3.1 CD45RA Depletion -- 19.2.3.2 DLI in Relapse -- 19.2.3.3 DLI in Mixed Chimerism -- 19.2.3.4 Virus-Specific T Cells -- 19.3 Regulatory Issues -- References. , 20: Documentation of Engraftment and Chimerism After HSCT.

Additional Edition: Print version: Carreras, Enric The EBMT Handbook Cham : Springer International Publishing AG,c2019 ISBN 9783030022778

Language: English

Keywords: Electronic books.

URL: Click to View

UID:

Format: 1 online resource (XL, 702 p. 56 illus., 38 illus. in color.)

Edition: 7th ed. 2019.

ISBN: 3-030-02278-1

Content: This Open Access 7th edition of the European Society for Blood and Marrow Transplantation (EBMT) handbook addresses the latest developments and innovations in hematopoietic stem cell transplantation and cellular therapy. Consisting of 93 chapters, it has been written by 175 leading experts in the field. Discussing all types of stem cell and bone marrow transplantation, including haplo-identical stem cell and cord blood transplantation, it also covers the indications for transplantation, the management of early and late complications as well as the new and rapidly evolving field of cellular therapies. This book provides an unparalleled description of current practices to enhance readers’ knowledge and practice skills.

Note: Part 1. Introduction -- 1. HSCT: Historical perspective -- 2. The EBMT: History, present and future -- 3. The role of unrelated donor registries in HSCT -- 4. The HSCT Unit -- 5. JACIE accreditation of HSCT programs -- 6. Statistical methods in HSCT and Cellular Therapies -- Part 2. Biological aspects -- 7. Biological properties of HSC: scientific basis for HSCT -- 8. Biological properties of cells other than HSC -- 9. Histocompatibility -- 10. Clinical & biological concepts for mastering Immune reconstitution after HSCT: towards practical guidelines and greater harmonization -- Part 3. Methodology and clinical aspects -- 11. Evaluation and counselling of candidates -- 12. Donor selection for adults and pediatrics -- 13. Conditioning -- 14. Bone marrow harvesting for HSCT -- 15. Mobilization and collection of HSC -- 16. Collection of HSC in children -- 17. Processing, cryopreserving, and controlling the quality of HSCs -- 18. Procurement and management of cord blood -- 19. Graft manipulation -- 20. Documentation of engraftment and chimerism after HSCT -- 21. Short and long-term controls after HSCT -- Part 4. General management of the patient -- 22. Vascular access -- 23. Transfusion support -- 24. Nutritional support -- 25. GVHD prophylaxis (immunosuppression) -- 26. Management ATG (SIRS) -- 27. Infections control and isolation procedures -- 28. General management of the patient; Specific aspects of children -- 29. Vaccinations -- 30. Psychological morbidity and support -- 31. Clinical relevant drug interactions in HSCT -- 32. Role of nursing in HSCT -- 33. Ethical issues in HSCT -- 34. Quality of life assessment after HSCT for pediatric and adults -- Part 5. HSCT complications and management -- 35. Neutropenic fever -- 36. Bacterial infections -- 37. Invasive fungal infections -- 38. Viral infections -- 39. Other life-threatening infections -- 40. Bleeding and thrombotic complications -- 41. Graft failure -- 42. Early complications of endothelial origin -- 43. Acute Graft-versus-Host Disease -- 44. Chronic Graft-versus-Host Disease -- 45. Post-transplant lymphoproliferative syndromes -- 46. Iron overload -- 47. Secondary neoplasia (other than PTLPS) -- Part 6. Specific organ complications -- 48. Ocular and oral complications -- 49. Hepatic complications -- 50. Gastrointestinal complications -- 51. Hemorrhagic cystitis and renal dysfunction -- 52. Non-infectious pulmonary complications -- 53. Neurological complications -- 54. Skin, hair and musculoskeletal complications -- 55. Cardiovascular diseases and metabolic syndrome -- 56. Endocrine disorders, fertility and sexual health -- Part 7. Prevention and management of relapse -- 57. Monitoring MRD in ALL and AML -- 58. Preventing/treating relapse with drugs -- 59. Delayed transfer of immune cells, or the art of Donor Lymphocyte Infusion -- 60. Cellular therapy with engineered T cells, efficacy and side effects -- 61. Mechanisms of Immune resistance -- 62. Regulatory Aspects of ATMP versus minimally manipulated immune cells -- Part 8. Specific modalities of HSCT and management -- 63. At-home HSCT -- 64. Umbilical cord blood transplantation in children and adults -- 65. Haploidentical HSCT -- 66. Photopheresis in adults and pediatrics -- 67. Overweight and obese patients -- 68. HSCT in elderly patients -- Part 9. Indications and results -- 69. Acute Myeloid Leukemia in adults -- 70. Acute Myeloid Leukemia in children -- 71. Acute Lymphoblastic Leukemia in adults -- 72. Acute lymphoblastic leukemia in children and adolescents -- 73. Myelodysplastic syndromes -- 74. Pediatric MDS including Refractory Cytopenia and Juvenile Myelomonocytic Leukemia -- 75. Myelodysplastic/myeloproliferative neoplasms -- 76. Myeloproliferative neoplasms -- 77. Severe aplastic anemia and PNH -- 78. Fanconi anemia and other hereditary Bone Marrow Failure syndromes -- 79. Hemoglobinopathies (Sickle Cell Disease and Thalassemia) -- 80. Multiple myeloma -- 81. Systemic light chain amyloidosis -- 82. POEMS syndrome and disease produced by other monoclonal immunoglobulins -- 83. Follicular lymphoma -- 84. Chronic lymphocytic leukemia -- 85. Diffuse large B cell lymphoma -- 86. Mantle cell lymphoma -- 87. Other T- and B-aggressive lymphomas and lymphomas associated to HIV -- 88. Classical Hodgkin’s lymphoma -- 89. Primary immunodeficiencies -- 90. Inborn error of metabolism and osteopetrosis -- 91. Autoimmune disease -- 92. Solid tumors. , English

Additional Edition: ISBN 3-030-02277-3

Language: English

DOI: 10.1007/978-3-030-02278-5

UID:

Format: 1 online resource (XL, 702 p. 56 illus., 38 illus. in color.)

Edition: 7th ed. 2019.

ISBN: 3-030-02278-1

Content: This Open Access 7th edition of the European Society for Blood and Marrow Transplantation (EBMT) handbook addresses the latest developments and innovations in hematopoietic stem cell transplantation and cellular therapy. Consisting of 93 chapters, it has been written by 175 leading experts in the field. Discussing all types of stem cell and bone marrow transplantation, including haplo-identical stem cell and cord blood transplantation, it also covers the indications for transplantation, the management of early and late complications as well as the new and rapidly evolving field of cellular therapies. This book provides an unparalleled description of current practices to enhance readers’ knowledge and practice skills.

Note: Part 1. Introduction -- 1. HSCT: Historical perspective -- 2. The EBMT: History, present and future -- 3. The role of unrelated donor registries in HSCT -- 4. The HSCT Unit -- 5. JACIE accreditation of HSCT programs -- 6. Statistical methods in HSCT and Cellular Therapies -- Part 2. Biological aspects -- 7. Biological properties of HSC: scientific basis for HSCT -- 8. Biological properties of cells other than HSC -- 9. Histocompatibility -- 10. Clinical & biological concepts for mastering Immune reconstitution after HSCT: towards practical guidelines and greater harmonization -- Part 3. Methodology and clinical aspects -- 11. Evaluation and counselling of candidates -- 12. Donor selection for adults and pediatrics -- 13. Conditioning -- 14. Bone marrow harvesting for HSCT -- 15. Mobilization and collection of HSC -- 16. Collection of HSC in children -- 17. Processing, cryopreserving, and controlling the quality of HSCs -- 18. Procurement and management of cord blood -- 19. Graft manipulation -- 20. Documentation of engraftment and chimerism after HSCT -- 21. Short and long-term controls after HSCT -- Part 4. General management of the patient -- 22. Vascular access -- 23. Transfusion support -- 24. Nutritional support -- 25. GVHD prophylaxis (immunosuppression) -- 26. Management ATG (SIRS) -- 27. Infections control and isolation procedures -- 28. General management of the patient; Specific aspects of children -- 29. Vaccinations -- 30. Psychological morbidity and support -- 31. Clinical relevant drug interactions in HSCT -- 32. Role of nursing in HSCT -- 33. Ethical issues in HSCT -- 34. Quality of life assessment after HSCT for pediatric and adults -- Part 5. HSCT complications and management -- 35. Neutropenic fever -- 36. Bacterial infections -- 37. Invasive fungal infections -- 38. Viral infections -- 39. Other life-threatening infections -- 40. Bleeding and thrombotic complications -- 41. Graft failure -- 42. Early complications of endothelial origin -- 43. Acute Graft-versus-Host Disease -- 44. Chronic Graft-versus-Host Disease -- 45. Post-transplant lymphoproliferative syndromes -- 46. Iron overload -- 47. Secondary neoplasia (other than PTLPS) -- Part 6. Specific organ complications -- 48. Ocular and oral complications -- 49. Hepatic complications -- 50. Gastrointestinal complications -- 51. Hemorrhagic cystitis and renal dysfunction -- 52. Non-infectious pulmonary complications -- 53. Neurological complications -- 54. Skin, hair and musculoskeletal complications -- 55. Cardiovascular diseases and metabolic syndrome -- 56. Endocrine disorders, fertility and sexual health -- Part 7. Prevention and management of relapse -- 57. Monitoring MRD in ALL and AML -- 58. Preventing/treating relapse with drugs -- 59. Delayed transfer of immune cells, or the art of Donor Lymphocyte Infusion -- 60. Cellular therapy with engineered T cells, efficacy and side effects -- 61. Mechanisms of Immune resistance -- 62. Regulatory Aspects of ATMP versus minimally manipulated immune cells -- Part 8. Specific modalities of HSCT and management -- 63. At-home HSCT -- 64. Umbilical cord blood transplantation in children and adults -- 65. Haploidentical HSCT -- 66. Photopheresis in adults and pediatrics -- 67. Overweight and obese patients -- 68. HSCT in elderly patients -- Part 9. Indications and results -- 69. Acute Myeloid Leukemia in adults -- 70. Acute Myeloid Leukemia in children -- 71. Acute Lymphoblastic Leukemia in adults -- 72. Acute lymphoblastic leukemia in children and adolescents -- 73. Myelodysplastic syndromes -- 74. Pediatric MDS including Refractory Cytopenia and Juvenile Myelomonocytic Leukemia -- 75. Myelodysplastic/myeloproliferative neoplasms -- 76. Myeloproliferative neoplasms -- 77. Severe aplastic anemia and PNH -- 78. Fanconi anemia and other hereditary Bone Marrow Failure syndromes -- 79. Hemoglobinopathies (Sickle Cell Disease and Thalassemia) -- 80. Multiple myeloma -- 81. Systemic light chain amyloidosis -- 82. POEMS syndrome and disease produced by other monoclonal immunoglobulins -- 83. Follicular lymphoma -- 84. Chronic lymphocytic leukemia -- 85. Diffuse large B cell lymphoma -- 86. Mantle cell lymphoma -- 87. Other T- and B-aggressive lymphomas and lymphomas associated to HIV -- 88. Classical Hodgkin’s lymphoma -- 89. Primary immunodeficiencies -- 90. Inborn error of metabolism and osteopetrosis -- 91. Autoimmune disease -- 92. Solid tumors. , English

Additional Edition: ISBN 3-030-02277-3

Language: English

DOI: 10.1007/978-3-030-02278-5

UID:

Format: 1 online resource (XL, 702 p. 56 illus., 38 illus. in color.)

Edition: 7th ed. 2019.

ISBN: 3-030-02278-1

Content: This Open Access 7th edition of the European Society for Blood and Marrow Transplantation (EBMT) handbook addresses the latest developments and innovations in hematopoietic stem cell transplantation and cellular therapy. Consisting of 93 chapters, it has been written by 175 leading experts in the field. Discussing all types of stem cell and bone marrow transplantation, including haplo-identical stem cell and cord blood transplantation, it also covers the indications for transplantation, the management of early and late complications as well as the new and rapidly evolving field of cellular therapies. This book provides an unparalleled description of current practices to enhance readers’ knowledge and practice skills.

Note: Part 1. Introduction -- 1. HSCT: Historical perspective -- 2. The EBMT: History, present and future -- 3. The role of unrelated donor registries in HSCT -- 4. The HSCT Unit -- 5. JACIE accreditation of HSCT programs -- 6. Statistical methods in HSCT and Cellular Therapies -- Part 2. Biological aspects -- 7. Biological properties of HSC: scientific basis for HSCT -- 8. Biological properties of cells other than HSC -- 9. Histocompatibility -- 10. Clinical & biological concepts for mastering Immune reconstitution after HSCT: towards practical guidelines and greater harmonization -- Part 3. Methodology and clinical aspects -- 11. Evaluation and counselling of candidates -- 12. Donor selection for adults and pediatrics -- 13. Conditioning -- 14. Bone marrow harvesting for HSCT -- 15. Mobilization and collection of HSC -- 16. Collection of HSC in children -- 17. Processing, cryopreserving, and controlling the quality of HSCs -- 18. Procurement and management of cord blood -- 19. Graft manipulation -- 20. Documentation of engraftment and chimerism after HSCT -- 21. Short and long-term controls after HSCT -- Part 4. General management of the patient -- 22. Vascular access -- 23. Transfusion support -- 24. Nutritional support -- 25. GVHD prophylaxis (immunosuppression) -- 26. Management ATG (SIRS) -- 27. Infections control and isolation procedures -- 28. General management of the patient; Specific aspects of children -- 29. Vaccinations -- 30. Psychological morbidity and support -- 31. Clinical relevant drug interactions in HSCT -- 32. Role of nursing in HSCT -- 33. Ethical issues in HSCT -- 34. Quality of life assessment after HSCT for pediatric and adults -- Part 5. HSCT complications and management -- 35. Neutropenic fever -- 36. Bacterial infections -- 37. Invasive fungal infections -- 38. Viral infections -- 39. Other life-threatening infections -- 40. Bleeding and thrombotic complications -- 41. Graft failure -- 42. Early complications of endothelial origin -- 43. Acute Graft-versus-Host Disease -- 44. Chronic Graft-versus-Host Disease -- 45. Post-transplant lymphoproliferative syndromes -- 46. Iron overload -- 47. Secondary neoplasia (other than PTLPS) -- Part 6. Specific organ complications -- 48. Ocular and oral complications -- 49. Hepatic complications -- 50. Gastrointestinal complications -- 51. Hemorrhagic cystitis and renal dysfunction -- 52. Non-infectious pulmonary complications -- 53. Neurological complications -- 54. Skin, hair and musculoskeletal complications -- 55. Cardiovascular diseases and metabolic syndrome -- 56. Endocrine disorders, fertility and sexual health -- Part 7. Prevention and management of relapse -- 57. Monitoring MRD in ALL and AML -- 58. Preventing/treating relapse with drugs -- 59. Delayed transfer of immune cells, or the art of Donor Lymphocyte Infusion -- 60. Cellular therapy with engineered T cells, efficacy and side effects -- 61. Mechanisms of Immune resistance -- 62. Regulatory Aspects of ATMP versus minimally manipulated immune cells -- Part 8. Specific modalities of HSCT and management -- 63. At-home HSCT -- 64. Umbilical cord blood transplantation in children and adults -- 65. Haploidentical HSCT -- 66. Photopheresis in adults and pediatrics -- 67. Overweight and obese patients -- 68. HSCT in elderly patients -- Part 9. Indications and results -- 69. Acute Myeloid Leukemia in adults -- 70. Acute Myeloid Leukemia in children -- 71. Acute Lymphoblastic Leukemia in adults -- 72. Acute lymphoblastic leukemia in children and adolescents -- 73. Myelodysplastic syndromes -- 74. Pediatric MDS including Refractory Cytopenia and Juvenile Myelomonocytic Leukemia -- 75. Myelodysplastic/myeloproliferative neoplasms -- 76. Myeloproliferative neoplasms -- 77. Severe aplastic anemia and PNH -- 78. Fanconi anemia and other hereditary Bone Marrow Failure syndromes -- 79. Hemoglobinopathies (Sickle Cell Disease and Thalassemia) -- 80. Multiple myeloma -- 81. Systemic light chain amyloidosis -- 82. POEMS syndrome and disease produced by other monoclonal immunoglobulins -- 83. Follicular lymphoma -- 84. Chronic lymphocytic leukemia -- 85. Diffuse large B cell lymphoma -- 86. Mantle cell lymphoma -- 87. Other T- and B-aggressive lymphomas and lymphomas associated to HIV -- 88. Classical Hodgkin’s lymphoma -- 89. Primary immunodeficiencies -- 90. Inborn error of metabolism and osteopetrosis -- 91. Autoimmune disease -- 92. Solid tumors. , English

Additional Edition: ISBN 3-030-02277-3

Language: English

DOI: 10.1007/978-3-030-02278-5